9.1 Cancer Pain Assessment & Comprehensive Analgesic Management

Cancer Pain Assessment & Comprehensive Analgesic Management

Cancer pain is a complex, multidimensional symptom experienced by up to 70-90% of patients with advanced malignancy. Effective management by Advanced Practice Registered Nurses (APRNs) requires a systematic clinical assessment, precise neurobiological classification, evidence-based application of the World Health Organization (WHO) analgesic ladder, individualization of opioid equianalgesic rotations, and aggressive prevention of opioid-induced adverse effects.

---

1. Comprehensive Cancer Pain Assessment & Pathophysiology

A thorough pain evaluation must be conducted at every clinical encounter using validated tools such as the Brief Pain Inventory (BPI) or the PQRST/OLDCARTS framework. Pain must be differentiated based on its underlying neurobiological mechanisms:

• Nociceptive Somatic Pain: Arises from mechanical, thermal, or chemical activation of nociceptors in skin, bone, muscle, or soft tissue (e.g., bone metastases, surgical wounds). Characterized as localized, aching, throbbing, or gnawing.
• Nociceptive Visceral Pain: Caused by stretching, ischemia, or inflammation of visceral organs or capsular structures (e.g., hepatic capsule distension, bowel obstruction, pancreatic carcinoma). Characterized as dull, poorly localized, deep cramping, or pressure, often associated with referred pain pathways.
• Neuropathic Pain: Resulting from direct structural damage, compression, or inflammation of peripheral nerves, plexus structures, or the central nervous system (e.g., malignant radiculopathy, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy). Characterized as burning, lancinating, electric shock-like, shooting, or accompanied by allodynia and hyperalgesia.
• Inflammatory Pain: Mediated by tumor-secreted cytokines, prostaglandins, and bradykinin surrounding surrounding tissues.

Temporal Patterns of Cancer Pain

• Persistent (Baseline) Pain: Pain present for $\ge 12$ hours per day of moderate-to-severe intensity when unmedicated.
• Breakthrough Pain (BTP): A transient flare of moderate-to-severe pain occurring over a background of controlled persistent pain. Subtypes include:
  • Incident Pain: Triggered by specific voluntary movements (e.g., walking with vertebral metastases) or involuntary actions (e.g., coughing).
  • Idiopathic (Spontaneous) Pain: Unpredictable pain flares lacking identifiable triggers.
  • End-of-Dose Failure: Pain recurring prior to the next scheduled dose of a long-acting analgesic, indicating inadequate baseline dosing rather than true BTP.

---

2. The WHO Analgesic Ladder & NCCN Guidelines

The WHO Analgesic Ladder provides a validated, stepwise framework for managing cancer pain based on self-reported pain intensity scores (0-10 scale):

Dosing Principles for Step 3 Opioids

1. Around-the-Clock (ATC) Dosing: Continuous persistent pain requires scheduled, long-acting (extended-release) opioids to maintain therapeutic plasma steady-state concentrations.
2. Breakthrough Pain Dosing: Every ATC regimen must include an immediate-release (IR) short-acting opioid prescribed PRN. The standard single BTP dose is calculated as 10% to 15% of the total 24-hour scheduled oral morphine equivalent (OME), administered Q2-4H PRN.

---

3. Opioid Equianalgesic Conversion & Rotation Protocols

Opioid rotation is indicated when a patient experiences intolerable opioid-related toxicities, unmanageable pain despite dose escalation, organ dysfunction, or financial/formulation barriers. Conversion relies on standardized equianalgesic reference values:

Step-by-Step Opioid Rotation Algorithm

1. Calculate Total 24-Hour Current Opioid Consumption: Sum all scheduled doses plus PRN doses used over the preceding 24 hours.
2. Convert Total Consumption to 24-Hour Oral Morphine Equivalent (OME): Multiply by the equianalgesic ratio.
3. Convert 24-Hour OME to the New Target Opioid: Multiply by the ratio of the target opioid.
4. Apply Mandatory Reduction for Incomplete Cross-Tolerance: Reduce the calculated daily target dose by 25% to 50%. Clinical nuance: If pain is severe and uncontrolled, reduce by 15-25%; if pain is well-controlled or rotating for toxicity, reduce by 30-50%.
5. Divide Target Daily Dose into Scheduled Regimen: Divide by dosing frequency (e.g., BID for ER tablets, Q72H for fentanyl patch).
6. Calculate New Immediate-Release Breakthrough Dose: Prescribe 10-15% of the new 24-hour total target dose Q2-4H PRN.

---

4. Unique Opioid Pharmacology: Methadone & Fentanyl

Methadone

• Mechanism: Synthetic opioid acting as a $\mu$-opioid receptor agonist, N-methyl-D-aspartate (NMDA) receptor antagonist, and serotonin/norepinephrine reuptake inhibitor (SNRI). This dual action renders methadone exceptionally effective for neuropathic and opioid-resistant cancer pain.
• Pharmacokinetics: High lipophilicity with rapid tissue redistribution. Elimination half-life ranges from 15 to 120 hours, significantly exceeding its analgesic duration (4-8 hours). Accumulation can occur over 3 to 5 days, risking delayed fatal respiratory depression.
• Equianalgesic Conversion: Non-linear! Higher OME requires a higher conversion ratio (e.g., OME <100 mg ratio is 3:1; OME 100-300 mg ratio is 5-10:1; OME >1000 mg ratio is 20:1).
• Safety & Toxicity: Methadone causes dose-dependent QTc prolongation and Torsades de Pointes. Baseline ECG is required prior to initiation (caution if QTc >460 ms, hold/discontinue if QTc >500 ms).

Transdermal Fentanyl

• Indications: Indicated ONLY for opioid-tolerant patients (defined as receiving at least 60 mg oral morphine daily, 25 mg oral oxycodone daily, or 8 mg oral hydromorphone daily for $\ge 1$ week).
• Dosing & Onset: 25 mcg/hr patch is roughly equivalent to 60 mg oral OME/24 hours. Depot formation in subcutaneous fat results in a 12 to 24-hour delayed onset of peak effect and a 12 to 24-hour elimination half-life after patch removal.
• Contraindications: Never use in opioid-naive patients, acute uncontrolled pain, or severe diaphoresis/fever (heat increases transdermal absorption rapidly, causing overdose).

---

5. Adjuvant Analgesics & Toxicity Management

Adjuvant Medications

• Gabapentinoids (Gabapentin, Pregabalin): First-line for neuropathic pain. Require renal dose adjustment.
• SNRIs (Duloxetine): First-line evidence-based agent for chemotherapy-induced peripheral neuropathy (CIPN).
• Corticosteroid (Dexamethasone): Potent anti-inflammatory effect; indicated for bone pain, capsular distension, and epidural spinal cord compression.
• Bone-Targeted Agents (Zoledronic acid, Denosumab): Reduce skeletal-related events and bone pain.

Opioid Toxicity Prevention & Management

• Opioid-Induced Constipation (OIC): Universal toxicity; tolerance does NOT develop. Prophylactic bowel regimen (stimulant laxative e.g., senna + stool softener e.g., docusate) must be initiated concurrently with opioids. For refractory OIC, prescribe Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs: methylnaltrexone 12 mg SC daily or naldemedine 0.2 mg PO daily), which block peripheral intestinal $\mu$-receptors without compromising central analgesia.
• Opioid Neurotoxicity (OIN): Manifests as severe sedation, cognitive impairment, myoclonus, hyperalgesia, and delirium due to accumulation of active toxic metabolites (e.g., morphine-3-glucuronide [M3G] or hydromorphone-3-glucuronide [H3G]). Managed with aggressive IV hydration, dose reduction, and opioid rotation.